{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:05:13Z","timestamp":1790283913602,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ajpc.2026.101790","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T23:56:16Z","timestamp":1786492576000},"page":"101790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical considerations on the use of evinacumab for the treatment of homozygous familial hypercholesterolemia"],"prefix":"10.1016","volume":"30","author":[{"given":"Archna","family":"Bajaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2698-7144","authenticated-orcid":false,"given":"Michael","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Shugg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2542-9930","authenticated-orcid":false,"given":"Richard","family":"Godin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Underberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ajpc.2026.101790_bib0006","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.5551\/jat.RV17065","article-title":"Advancements in the treatment of homozygous familial hypercholesterolemia","volume":"29","author":"Bajaj","year":"2022","journal-title":"J Atheroscler Thromb"},{"issue":"2","key":"10.1016\/j.ajpc.2026.101790_bib0007","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/MED.0000000000000590","article-title":"Novel therapies for familial hypercholesterolemia","volume":"28","author":"Mohamed","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"7","key":"10.1016\/j.ajpc.2026.101790_bib0008","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1194\/jlr.M054890","article-title":"ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys","volume":"56","author":"Gusarova","year":"2015","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.ajpc.2026.101790_bib0009","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jacl.2026.01.011","article-title":"Update on familial hypercholesterolemia: an expert clinical consensus from the National lipid association","volume":"20","author":"Ahmad","year":"2026","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ajpc.2026.101790_bib0010","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.atherosclerosis.2018.06.855","article-title":"Epidemiology of familial hypercholesterolaemia: community and clinical","volume":"277","author":"Vallejo-Vaz","year":"2018","journal-title":"Atherosclerosis"},{"issue":"32","key":"10.1016\/j.ajpc.2026.101790_bib0011","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.ajpc.2026.101790_bib0012","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 update on European atherosclerosis society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"issue":"32","key":"10.1016\/j.ajpc.2026.101790_bib0013","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the European atherosclerosis society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"issue":"36","key":"10.1016\/j.ajpc.2026.101790_bib0014","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.ajpc.2026.101790_bib0015","first-page":"e1154","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"153","author":"Blumenthal","year":"2026","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.ajpc.2026.101790_bib0016","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ajpc.2026.101790_bib0017","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jacl.2024.11.003","article-title":"Ezetimibe in the management of homozygous familial hypercholesterolaemia","volume":"19","author":"Mansfield","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"9965","key":"10.1016\/j.ajpc.2026.101790_bib0018","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ajpc.2026.101790_bib0019","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","article-title":"Long-term evolocumab in patients with familial hypercholesterolemia","volume":"75","author":"Santos","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ajpc.2026.101790_bib0020","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial","volume":"76","author":"Blom","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"9860","key":"10.1016\/j.ajpc.2026.101790_bib0021","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ajpc.2026.101790_bib0022","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ajpc.2026.101790_bib0023","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ajpc.2026.101790_bib0024","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ajpc.2026.101790_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100648","article-title":"The long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia","volume":"2","author":"Raal","year":"2023","journal-title":"JACC Adv"},{"issue":"27","key":"10.1016\/j.ajpc.2026.101790_bib0026","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehae325","article-title":"Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy","volume":"45","author":"Gaudet","year":"2024","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.ajpc.2026.101790_bib0027","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","article-title":"Evinacumab for pediatric patients with homozygous familial hypercholesterolemia","volume":"149","author":"Wiegman","year":"2024","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ajpc.2026.101790_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2024.04.088","article-title":"The long-term efficacy and safety of evinacumab in pediatric patients with homozygous familial hypercholesterolemia","volume":"18","author":"Greber-Platzer","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"17","key":"10.1016\/j.ajpc.2026.101790_bib0029","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/eurjpc\/zwad203","article-title":"Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia","volume":"30","author":"Gu","year":"2023","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"10.1016\/j.ajpc.2026.101790_bib0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacl.2011.03.001","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National lipid association expert panel on familial hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.ajpc.2026.101790_bib0031","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1\u2013full report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"24","key":"10.1016\/j.ajpc.2026.101790_bib0032","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology\/American heart association Task Force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101790_bib0033","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"42","key":"10.1016\/j.ajpc.2026.101790_bib0034","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.ajpc.2026.101790_bib0035","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.3390\/cells12121648","article-title":"A review of progress on targeting LDL receptor-dependent and -independent pathways for the treatment of hypercholesterolemia, a major risk factor of ASCVD","volume":"12","author":"Srivastava","year":"2023","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.ajpc.2026.101790_bib0036","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the American heart association","volume":"44","author":"Gianos","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ajpc.2026.101790_bib0037","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwag182","article-title":"Evinacumab with or without lipoprotein apheresis in homozygous familial hypercholesterolaemia","author":"Moriarty","year":"2026","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"10.1016\/j.ajpc.2026.101790_bib0038","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13836","article-title":"Evinacumab: mechanism of action, clinical, and translational science","volume":"17","author":"Dingman","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"16","key":"10.1016\/j.ajpc.2026.101790_bib0039","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.ajpc.2026.101790_bib0040","doi-asserted-by":"crossref","first-page":"E1266","DOI":"10.1210\/jc.2012-1298","article-title":"Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization","volume":"97","author":"Minicocci","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ajpc.2026.101790_bib0041","series-title":"GeneReviews\u00ae [Internet]","article-title":"Familial combined hypolipidemia","author":"Burnett","year":"2023"},{"issue":"23","key":"10.1016\/j.ajpc.2026.101790_bib0042","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajpc.2026.101790_bib0043","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101790_bib0044","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010168","article-title":"Evinacumab, an ANGPTL3 inhibitor, in the treatment of dyslipidemia","volume":"12","author":"Sosnowska","year":"2022","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.ajpc.2026.101790_bib0045","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1161\/ATVBAHA.124.322364","article-title":"Real-world effectiveness and safety of evinacumab in children and adults with homozygous familial hypercholesterolemia: a multisite US perspective\u2014brief report","volume":"45","author":"Wilkinson","year":"2025","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"10.1016\/j.ajpc.2026.101790_bib0064","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","volume":"61","author":"Adam","year":"2020","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.ajpc.2026.101790_bib0065","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1006\/geno.1999.6041","article-title":"Identification of a mammalian angiopoietin-related protein expressed specifically in liver","volume":"62","author":"Conklin","year":"1999","journal-title":"Genomics"},{"issue":"2","key":"10.1016\/j.ajpc.2026.101790_bib0066","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ng814","article-title":"Angptl3 regulates lipid metabolism in mice","volume":"30","author":"Koishi","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.ajpc.2026.101790_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120627","article-title":"Evinacumab in patients aged 5\u201317 years with homozygous familial hypercholesterolemia","volume":"413","author":"Rosenson","year":"2026","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ajpc.2026.101790_bib0047","series-title":"94th European Atherosclerosis Society Congress","article-title":"Adverse events in the evinacumab clinical development programme in homozygous Familial hypercholesterolaemia (HoFH): focus on immunogenicity, liver function, and pregnancy","author":"Jones","year":"2026"},{"key":"10.1016\/j.ajpc.2026.101790_bib0048","series-title":"Review of infusion reactions following evinacumab treatment in patients with homozygous familial hypercholesterolemia and implications for prevention and management","author":"Hughes","year":"2026"},{"issue":"5","key":"10.1016\/j.ajpc.2026.101790_bib0049","doi-asserted-by":"crossref","first-page":"e817","DOI":"10.1016\/j.jacl.2024.05.006","article-title":"Real-world experience of long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and untreated with lipoprotein apheresis","volume":"18","author":"Stefanutti","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ajpc.2026.101790_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119234","article-title":"Evinacumab and reduced lipoprotein apheresis in pediatric homozygous familial hypercholesterolemia: a retrospective study on LDL-C","volume":"406","author":"Nigmann","year":"2025","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.ajpc.2026.101790_bib0051","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/psp4.70017","article-title":"Comparison of model-predicted and observed evinacumab pharmacokinetics and efficacy in children aged <\u20095\u2009years with homozygous familial hypercholesterolemia","volume":"14","author":"Bihorel","year":"2025","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"10","key":"10.1016\/j.ajpc.2026.101790_bib0052","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jcmg.2024.05.005","article-title":"Decreased LDL-cholesterol exposure following ANGPTL3 inhibition reduces coronary plaque development in homozygous familial hypercholesterolemia","volume":"17","author":"Schonck","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101790_bib0053","article-title":"Atherosclerotic plaque regression in homozygous familial hypercholesterolaemia: a case report of a long-term lipid-lowering therapy involving LDL-receptor-independent mechanisms","volume":"7","author":"Khoury","year":"2023","journal-title":"Eur Heart J Case Rep"},{"issue":"5","key":"10.1016\/j.ajpc.2026.101790_bib0063","first-page":"1457","article-title":"Simulation model to estimate pretreatment (baseline) low-density lipoprotein cholesterol levels in people living with homozygous familial hypercholesterolemia","volume":"19","author":"Gu","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10.1016\/j.ajpc.2026.101790_bib0054","article-title":"Intensive combination LDL-lowering therapy in a patient with homozygous familial hypercholesterolemia","volume":"29","author":"Tada","year":"2024","journal-title":"JACC Case Rep"},{"key":"10.1016\/j.ajpc.2026.101790_bib0055","article-title":"Therapeutic plasma exchange and evinacumab for homozygous familial hypercholesterolemia","author":"Raygani","year":"2025","journal-title":"JACC Case Rep"},{"key":"10.1016\/j.ajpc.2026.101790_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2020.10.119","article-title":"Evaluating the effect of lipid-apheresis on evinacumab and angiopoietin-like 3 (ANGPTL3) levels","volume":"315","author":"Moriarty","year":"2020","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.ajpc.2026.101790_bib0057","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.21873\/anticanres.14062","article-title":"Systematic review on infusion reactions to and infusion rate of monoclonal antibodies used in cancer treatment","volume":"40","author":"Rombouts","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ajpc.2026.101790_bib0060","series-title":"Patient access planning with myRARE\u2122 for EVKEEZA\u00ae (evinacumab-dgnb)","year":"2025"},{"issue":"4","key":"10.1016\/j.ajpc.2026.101790_bib0061","first-page":"1009","article-title":"Global disparities in access to lipid-lowering therapies for patients with homozygous familial hypercholesterolemia - A physician survey","volume":"19","author":"Schonck","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ajpc.2026.101790_bib0062","series-title":"Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over. Technology Appraisal Guidance TA1002","year":"2024"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667726003648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667726003648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:57:14Z","timestamp":1790283434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667726003648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":59,"alternative-id":["S2666667726003648"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101790","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical considerations on the use of evinacumab for the treatment of homozygous familial hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101790"}}